Year in Review (*) Limited assurance by Deloitte. (**) As at 30 June 2025. Financial Research and development Growth through portfolio development and commercialisation with integrated project focused mindset. Delivered CSL’s portfolio. People Enable CSL’s people to deliver the company’s future. 24,434 (80%) respondents to 2025 Employee Engagement Survey. 72.9%* 2025 Engagement Index. Expansion of mental health benefits via a third party provider to 43 countries for employees and their families. CSL has launched the CSL Community Impact Awards, a new initiative designed to support not-for-profit community organisations focused on health in Australia. 816 participants in the Frontline Leader (FFL) Program 97,789 global recognition moments shared in Celebrate the Promise Program** RiaSTAP® AFD CSL’s human fibrinogen concentrate is making progress in the treatment of acquired fibrinogen deficiency (AFD). In October, the first patient was treated in the Phase III study to evaluate the effectiveness of RiaSTAP® in managing bleeding episodes and to assess its overall safety profile in these patients. Strategically locate capabilities that need to collaborate to increase productivity, reduce complexity and drive innovation. Consolidation of R&D sites to create 6 anchor sites in the US, UK, Switzerland and Australia. + READ MORE ABOUT CSL’S R&D PIPELINE AT WWW.CSL.COM/RESEARCH-ANDDEVELOPMENT/PRODUCT-PIPELINE NPATA attributable to equity holders of US$3.2 billion for the year ended 30 June 2025, up 11% on a reported currency basis when compared to the prior comparable period. Strong growth in immunoglobulins portfolio, up 7% at constant currency. US$11,158m CSL Behring revenue US$2,166m CSL Seqirus revenue US$2,234m CSL Vifor revenue Cashflow from operations was $3,561 million, up 29%. The increase was driven by overall growth in sales, higher profitability and improved working capital management. 8 Performance
RkJQdWJsaXNoZXIy MjE2NDg3